CA2598234A1 - Inhibition de la proteine-1 apparentee a frizzled induite par l'arni pour le traitement du glaucome - Google Patents
Inhibition de la proteine-1 apparentee a frizzled induite par l'arni pour le traitement du glaucome Download PDFInfo
- Publication number
- CA2598234A1 CA2598234A1 CA002598234A CA2598234A CA2598234A1 CA 2598234 A1 CA2598234 A1 CA 2598234A1 CA 002598234 A CA002598234 A CA 002598234A CA 2598234 A CA2598234 A CA 2598234A CA 2598234 A1 CA2598234 A1 CA 2598234A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- interfering rna
- nucleotides
- mrna corresponding
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66055605P | 2005-03-11 | 2005-03-11 | |
US60/660,556 | 2005-03-11 | ||
US68863305P | 2005-06-08 | 2005-06-08 | |
US60/688,633 | 2005-06-08 | ||
PCT/US2006/009000 WO2006099353A1 (fr) | 2005-03-11 | 2006-03-10 | Inhibition de la proteine-1 apparentee a frizzled induite par l'arni pour le traitement du glaucome |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2598234A1 true CA2598234A1 (fr) | 2006-09-21 |
Family
ID=36649793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002598234A Abandoned CA2598234A1 (fr) | 2005-03-11 | 2006-03-10 | Inhibition de la proteine-1 apparentee a frizzled induite par l'arni pour le traitement du glaucome |
Country Status (9)
Country | Link |
---|---|
US (5) | US7947660B2 (fr) |
EP (1) | EP1856259A1 (fr) |
JP (2) | JP2008533050A (fr) |
KR (1) | KR20080018858A (fr) |
AU (1) | AU2006223131A1 (fr) |
BR (1) | BRPI0609206A2 (fr) |
CA (1) | CA2598234A1 (fr) |
MX (1) | MX2007010608A (fr) |
WO (1) | WO2006099353A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1781787T3 (pl) | 2004-08-23 | 2018-01-31 | Sylentis Sau | Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA |
KR20080018858A (ko) * | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―1의 RNAⅰ-중재저해 |
GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
EP2192926A1 (fr) * | 2007-10-01 | 2010-06-09 | Alcon Research, Ltd. | Administration autocomplémentaire provoquée par aav de molécules d'arn interférentes pour traiter ou prévenir des troubles oculaires |
US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
WO2009065022A2 (fr) | 2007-11-15 | 2009-05-22 | Alcon Research, Ltd. | Administration d'arnic médiée par un récepteur de lipoprotéine basse densité |
AR069704A1 (es) | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | Sistema de administracion de rnai de interferencia y usos del mismo |
EP3520749A1 (fr) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Dispositif d'accès oculaire |
WO2012161677A1 (fr) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | Administration de petit arn interférent médié par la transferrine/le récepteur de la transferrine |
US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
ES2750125T3 (es) | 2012-09-05 | 2020-03-25 | Sylentis Sau | ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
MX2015005839A (es) | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
AU2014259694B2 (en) | 2013-05-03 | 2018-11-08 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
WO2014197317A1 (fr) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Appareil et procédés pour une administration de médicament à l'aide de multiples réservoirs |
WO2015132303A1 (fr) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Arnsi et leur utilisation dans des méthodes et des compositions pour le traitement et/ou la prévention d'affections oculaires |
WO2015196085A2 (fr) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Canule à diamètre variable et procédés de commande de profondeur d'insertion pour administration de médicaments |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
WO2017139375A1 (fr) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Kit d'injection oculaire, conditionnement et procédés d'utilisation |
JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
EP3496680A1 (fr) | 2016-08-12 | 2019-06-19 | Clearside Biomedical, Inc. | Dispositifs et procédés de réglage de la profondeur d'insertion d'une aiguille pour administration de médicament |
EP3917625A4 (fr) * | 2019-01-29 | 2023-06-21 | The Regents of The University of California | Nouveaux traitement du glaucome |
US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
WO2023239756A1 (fr) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Compositions de nanoparticules lipidiques et leurs utilisations |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506569B1 (en) | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP2314700A1 (fr) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US20080166356A9 (en) * | 1999-09-13 | 2008-07-10 | Peter Bodine | Pharmaceutical compositions and methods of using secreted frizzled related protein |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
PL208368B1 (pl) | 2000-02-29 | 2011-04-29 | Alcon Inc | Sposób diagnozowania jaskry |
DE10012340A1 (de) | 2000-03-14 | 2001-09-20 | Merck Patent Gmbh | Verfahren zur Baeyer-Villiger-Oxidation organischer Carbonylverbindungen |
CA2403397A1 (fr) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Procedes et compositions d'interference d'arn |
PT2796553T (pt) | 2000-03-30 | 2019-09-27 | Massachusetts Inst Technology | Mediadores de interferência de arn específicos de sequência de arn |
WO2002044321A2 (fr) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Petites molecules d'arn mediant l'interference arn |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
AU2004266311B2 (en) * | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
TWI335221B (en) | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
CN1602207A (zh) | 2001-12-11 | 2005-03-30 | 法布罗根股份有限公司 | 抑制眼病理过程的方法 |
WO2003092705A1 (fr) * | 2002-05-03 | 2003-11-13 | Alcon, Inc. | Diagnostic et traitement du glaucome et procedes de decouverte de nouveaux agents therapeutiques du glaucome bases sur la voie de signalisation wnt/ca2+ |
CA2524569C (fr) | 2002-05-03 | 2013-10-22 | Duke University | Procede de regulation de l'expression genique |
WO2003092475A2 (fr) | 2002-05-03 | 2003-11-13 | Alcon, Inc. | Diagnostiques et traitement du glaucome et procede permettant de decouvrir de nouveaux agents therapeutiques fondes sur la voie de signalisation de la polarite planaire des cellules (pcp) / wnt |
AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
AU2003264727A1 (en) | 2002-09-04 | 2004-03-29 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
US20040072769A1 (en) * | 2002-09-16 | 2004-04-15 | Yin James Qinwei | Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs |
PT2284266E (pt) * | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Siarn contra tp53 |
US20040175732A1 (en) | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
WO2004076639A2 (fr) * | 2003-02-26 | 2004-09-10 | Wyeth | Compositions et methodes destinees a diagnostiquer et traiter des maladies auto-immunes |
US20050203043A1 (en) | 2004-01-23 | 2005-09-15 | Dharmacon, Inc. | Identification of toxic nucleotide sequences |
GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
TWI386225B (zh) | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術 |
TWI401316B (zh) | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用 |
TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
KR20080018858A (ko) | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―1의 RNAⅰ-중재저해 |
-
2006
- 2006-03-10 KR KR1020077021405A patent/KR20080018858A/ko not_active Application Discontinuation
- 2006-03-10 EP EP06738105A patent/EP1856259A1/fr not_active Ceased
- 2006-03-10 CA CA002598234A patent/CA2598234A1/fr not_active Abandoned
- 2006-03-10 MX MX2007010608A patent/MX2007010608A/es active IP Right Grant
- 2006-03-10 US US11/373,376 patent/US7947660B2/en active Active
- 2006-03-10 JP JP2008501049A patent/JP2008533050A/ja not_active Withdrawn
- 2006-03-10 BR BRPI0609206-3A patent/BRPI0609206A2/pt not_active Application Discontinuation
- 2006-03-10 WO PCT/US2006/009000 patent/WO2006099353A1/fr active Application Filing
- 2006-03-10 AU AU2006223131A patent/AU2006223131A1/en not_active Abandoned
-
2011
- 2011-04-12 US US13/084,944 patent/US8173617B2/en active Active
-
2012
- 2012-03-26 US US13/429,913 patent/US9040494B2/en active Active
- 2012-07-10 JP JP2012154550A patent/JP2012193197A/ja active Pending
-
2015
- 2015-04-21 US US14/692,402 patent/US9550994B2/en active Active
-
2016
- 2016-11-30 US US15/364,992 patent/US20170073681A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170073681A1 (en) | 2017-03-16 |
WO2006099353A1 (fr) | 2006-09-21 |
AU2006223131A1 (en) | 2006-09-21 |
US9040494B2 (en) | 2015-05-26 |
BRPI0609206A2 (pt) | 2010-03-02 |
JP2008533050A (ja) | 2008-08-21 |
JP2012193197A (ja) | 2012-10-11 |
EP1856259A1 (fr) | 2007-11-21 |
US20060223773A1 (en) | 2006-10-05 |
US20110190381A1 (en) | 2011-08-04 |
KR20080018858A (ko) | 2008-02-28 |
US20120178795A1 (en) | 2012-07-12 |
US7947660B2 (en) | 2011-05-24 |
MX2007010608A (es) | 2007-10-19 |
US20150307882A1 (en) | 2015-10-29 |
US9550994B2 (en) | 2017-01-24 |
US8173617B2 (en) | 2012-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9550994B2 (en) | RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma | |
US20220364097A1 (en) | RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS | |
US20080051361A1 (en) | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions | |
US20120178794A1 (en) | RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders | |
JP2008533050A5 (fr) | ||
CA2595678A1 (fr) | Inhibition de cibles oculaires induite par interference arn | |
US20150057336A1 (en) | RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA | |
US9752147B2 (en) | RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions | |
WO2008067373A2 (fr) | Inhibition véhiculée par arni d'aquaporine 1 pour le traitement d'affections liées à l'iop | |
AU2012200976A1 (en) | RNAI-Mediated inhibition of frizzled related protein-1 for treatment of gluacoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20141020 |